|
Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) (USD $)
In Millions, unless otherwise specified |
Dec. 31, 2014
|
Jun. 30, 2014
|
|---|---|---|
| Inventory Valuation Reserves | $ 30.0us-gaap_InventoryValuationReserves | $ 30.0us-gaap_InventoryValuationReserves |
| Available-for-sale Securities, Amortized Cost Basis | 37.2us-gaap_AvailableForSaleSecuritiesAmortizedCost | 40.7us-gaap_AvailableForSaleSecuritiesAmortizedCost |
| Available-for-sale Securities | 51.1us-gaap_AvailableForSaleSecurities | 48.4us-gaap_AvailableForSaleSecurities |
| Chemo Centryx, Inc. [Member] | ||
| Available-for-sale Securities, Amortized Cost Basis |
29.5us-gaap_AvailableForSaleSecuritiesAmortizedCost / us-gaap_InvestmentTypeAxis = tech_ChemoCentryxIncMember |
29.5us-gaap_AvailableForSaleSecuritiesAmortizedCost / us-gaap_InvestmentTypeAxis = tech_ChemoCentryxIncMember |
| Available-for-sale Securities |
$ 43.4us-gaap_AvailableForSaleSecurities / us-gaap_InvestmentTypeAxis = tech_ChemoCentryxIncMember |
$ 37.1us-gaap_AvailableForSaleSecurities / us-gaap_InvestmentTypeAxis = tech_ChemoCentryxIncMember |
| X | ||||||||||
|
- Definition
Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of valuation reserve for inventory. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|